Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
C grade · PMID 41980674
View analysis →C grade · PMID 41973181
View analysis →C grade · PMID 41932383
View analysis →C grade · PMID 41994471
View analysis →C grade · PMID 41928915
View analysis →C grade · PMID 42011986
View analysis →C grade · PMID 41948610
View analysis →C grade · PMID 41897492
View analysis →C grade · PMID 41905903
View analysis →C grade · PMID 41968748
View analysis →Integrative analysis of substantia nigra transcriptomes from 22 PD and 22 controls across three GEO datasets identified 85 consensus differentially expressed mRNAs—including molecular chaperones (DNAJB1, HSPA1B/L), dopaminergic markers (TH, SLC6A3), ECM components—and 20 PPI hub genes, with…
The study prioritizes biologically plausible biomarkers and therapeutic targets tied to proteostasis and mitochondrial/dopaminergic dysfunction in PD, offering a focused candidate list for follow-up validation and target-driven drug discovery despite being limited to post-mortem,…
This in vitro study shows resveratrol-loaded polymeric nanoparticles protect PC12 cells and astrocytes from rotenone-induced oxidative stress, mitochondrial dysfunction, and apoptosis while modulating NRF2/HMOX-1 expression.
By improving resveratrol delivery and implicating NRF2-mediated antioxidant defense, the work identifies a mechanistically actionable neuroprotective approach relevant to Parkinson's research, though it remains early-stage and requires in vivo and translational validation.
In a paraquat+lectin rat 'body-first' PD model, 60 days of twice-daily levodopa/benserazide administered after established motor deficits produced no long-term changes in motor or visuospatial memory performance, nigral dopaminergic or medial septal cholinergic neuron loss, or phosphorylated…
Offers translationally relevant, if limited, preclinical evidence that chronic levodopa does not accelerate neurodegeneration or α-syn pathology in a body-first PD model, providing reassurance about levodopa safety and informing neuroprotection trial design and prioritization.
Multimodal PET study in 33 PD patients and 25 controls found expected striatal dopaminergic deficits and regional serotonergic reductions but no group differences or longitudinal change in synaptic density (11C‑UCB‑J), with limited clinical correlations.
Supports use of DAT and SERT imaging for phenotyping and trial stratification while the absence of detectable synaptic loss at mild–moderate stages informs biomarker selection and timing for neuroprotective therapeutic strategies.
Wearable gyro sensors during forearm rotation (but not finger tapping) revealed greater upper-limb motor asymmetry in early, drug‑naïve PD versus SWEDD, with asymmetry indices correlating with clinical motor scores.
This study offers a quantitative, noninvasive sensor biomarker for distinguishing PD from SWEDD and for patient stratification in diagnosis and clinical trials, aiding translational work and trial enrollment though it does not advance mechanistic or therapeutic targets.
Integrative single-nucleus RNA-seq across multiple neurodegenerative diseases defines a conserved inflammatory microglial transcriptional program and nominates SPP1 (osteopontin) as a conserved disease-associated microglial biomarker validated in mouse models.
Highlights microglial inflammation as a cross-disease, potentially targetable axis and provides a validated biomarker (SPP1) useful for patient stratification and monitoring microglial-modulating therapies in Parkinson's disease research, though it stops short of proposing direct therapeutic…
A review evaluating nanoengineered delivery systems (lipid, polymeric, vesicular, dendritic) to enhance brain bioavailability and therapeutic efficacy of plant-derived neuroprotective phytochemicals, integrating mechanistic rationale, preclinical/early clinical evidence, and translational…
By offering concrete design principles to overcome the blood–brain barrier and discussing translational hurdles, the paper is useful for informing Parkinson's-related drug-delivery strategies for neuroprotective compounds, though its review nature and limited PD-specific mechanistic data reduce…
The paper describes synthesis, in vitro screening, and molecular modeling of 2‑aroylbenzothiophene analogues that are selective hMAO‑B inhibitors (notably compounds 4, 11, 12) and show modest neuroprotection in SH‑SY5Y cells versus 6‑OHDA, but exhibit cytotoxicity/ROS generation at high micromolar…
Provides a novel chemotype and structural insights for selective MAO‑B inhibition—a validated Parkinson's target—offering a lead series for medicinal chemistry optimization toward neuroprotective agents, though potency, toxicity and in vivo validation remain unresolved.
This review argues that a "body-first" subtype of Parkinson's may begin in the GI tract—driven by environmental insults, α-synuclein misfolding, oxidative stress and enteric glial activation—that propagates retrogradely via the vagus to the brain and discusses implications for early gut-targeted…
By synthesizing evidence for enteric oxidative stress, glial activation, and α-synuclein propagation as early, potentially druggable events, the paper points to biomarkers and gut-directed or repurposed therapies that could enable earlier, disease-modifying interventions in PD.
This review advocates integrating peptidomics—high-resolution LC-MS/MS workflows and AI-driven peptide identification—into microbiome research to capture unstable host and microbial signaling peptides and proteolytic fragments that are missed by genomics/proteomics, with implications for biomarkers…
By revealing peptide mediators of host–microbiome communication and offering methods to discover disease-linked peptides, peptidomics can identify actionable biomarkers and novel peptide-based targets along the gut–brain axis that may inform Parkinson's disease biomarker development and therapeutic…
This review summarizes current knowledge on mitochondria-associated membranes (MAMs)/ER–mitochondria contacts, their roles in calcium signaling, ROS, autophagy, inflammation and lipid metabolism, and discusses how MAM dysfunction contributes to aging and age-related neurodegenerative diseases…
MAMs sit at the intersection of multiple Parkinson's-relevant pathways (mitochondrial dysfunction, impaired mitophagy/autophagy, calcium dysregulation and neuroinflammation), so synthesizing these mechanisms highlights actionable targets and pathways for therapeutic development and biomarker…
The paper shows that forming a silver(I) trimeric complex with Anle138b alters α-synuclein aggregation in PFF-treated cell cultures by selectively reducing a ~12.4 kDa C-terminal truncated α-synuclein species and increasing aggregate size/morphology relative to the parent compound.
This indicates metal complexation can modulate Anle138b's effects on pathogenic α-synuclein species and offers a novel chemical tool to study C-terminal truncation–driven aggregation, but the finding is currently limited to in vitro models and has unclear therapeutic translatability due to…
rAAV-mediated re-expression of Fbxo7 in a conditional Fbxo7 knockout mouse prevents and reverses progressive loss of nigrostriatal dopaminergic terminals, restoring TH and DAT immunoreactivity even after phenotype onset.
Provides strong preclinical evidence that gene replacement can reverse established dopaminergic terminal deficits in a genetic Parkinsonism model, supporting FBXO7-targeted gene therapy and a clinically relevant therapeutic window for neurorestorative interventions.
Recent clinical work indicates that dopaminergic progenitor cells derived from iPSCs or hESCs achieve graft survival and favorable safety with apparent absence of graft‑induced dyskinesia, though definitive clinical efficacy remains to be established in well‑designed trials.
This represents a highly translational cell‑replacement strategy that addresses key limitations of fetal grafts (ethical concerns and GID) and, if efficacy is confirmed, could provide durable restoration of nigrostriatal dopamine in Parkinson’s disease.
The authors report synthesis of chiral Co/Zn Schiff-base clusters (R/S-Co4Zn5L10 and related Co complexes) and show that R-enantiomers rescue dopaminergic neuron loss, improve dopamine-dependent locomotion, and inhibit α-synuclein aggregation in nematode Parkinson’s models.
Demonstrates mechanism-relevant (α‑synuclein aggregation inhibition) in vivo neuroprotective activity for a novel metal-based compound class, making it a promising early-stage lead for follow-up in mammalian models despite toxicity and translational uncertainties.
Registry study of cilta-cel in relapsed/refractory multiple myeloma shows high efficacy with substantial toxicity; importantly, 2.7% of patients developed Parkinsonism as a non-ICANS neurotoxicity.
Although not a Parkinson's study, the reported CAR-T–associated Parkinsonism is a clinically relevant signal that may inform immune- or cytokine-mediated mechanisms of basal ganglia dysfunction and could guide safety monitoring, modeling, or repurposing studies related to immune-driven parkinsonism.
Review of intranasal ethosomal nanocarriers for brain delivery that emphasizes ethanol-enhanced membrane fluidity, penetration enhancers, and functionalization to improve nose-to-brain transport, while noting mostly preclinical data and unresolved safety/absorption issues.
Intranasal ethosomes could enable noninvasive, targeted delivery of Parkinson's therapeutics (e.g., neuroprotective agents or biologics) to the brain and reduce systemic exposure, but translation is limited by safety concerns and lack of clinical validation.
A focused literature review (2018–2024) on hydrogel-forming microneedles for sustained transdermal delivery of small molecules, biologics, and nanocarriers to the CNS, describing device designs, successful preclinical payloads (including neurotrophic factors), smart integrations, and key…
Offers a practical, patient-friendly delivery platform that could noninvasively improve bioavailability and enable sustained or targeted delivery of neuroprotective agents for Parkinson's disease—bridging a translational gap—though payload capacity, consistent skin penetration, and scalable…
Large Scandinavian cohort study found that new users of GLP-1 receptor agonists had a lower incidence of Parkinson's disease than new users of sulfonylureas (adjusted HR 0.81, consistent across sensitivity analyses).
Supports the repurposing of GLP-1 receptor agonists as candidate neuroprotective therapies for Parkinson's disease with high translational potential given existing clinical safety data, though causality requires randomized trials and mechanistic studies to confirm.
The study demonstrates that COMT inhibitors exhibit iron-dependent antibiotic activity that reshapes gut microbiota and, in an individual-specific manner, alters microbiome-mediated L‑DOPA metabolism ex vivo, revealing a drug–microbiome–drug interaction.
By uncovering a mechanistic, potentially actionable route (iron-modulated antimicrobial effects of COMT‑Is) that impacts L‑DOPA metabolism, the work suggests opportunities to predict or mitigate variable patient responses to co‑prescribed Parkinson’s medications via microbiome profiling or targeted…
